Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2
Pharmaceutical Sciences and Drug Design · 2021 · 1 (1) · 10-26
DOI: 10.51847/wyyopukukf ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2021. Verfasst von Angelique Welman und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
The virus that creates COVID-19, SARS-CoV-2, is highly contagious and typically replicates in the upper and lower respiratory tract to cause atypical pneumonia in humans. The gastrointestinal and cardiovascular tissues that contain its primary binding receptor, ACE2, may also be infected. A variety of therapeutic approaches have been investigated and modified to reduce the potentially dangerous clinical consequences of the COVID-19 pandemic. However, there isn't a proven cure for this illnes
Zitieren
APA
Welman, A., & Outhoff, K. (2021). Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2. Pharmaceutical Sciences and Drug Design, 1(1), 10-26. https://doi.org/10.51847/wyyopukukf
Vancouver
Welman A, Outhoff K. Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2. Pharmaceutical Sciences and Drug Design. 2021;1(1):10-26. doi:10.51847/wyyopukukf
BibTeX
@article{Welman2021,
author = {Welman, Angelique and Outhoff, Kim},
title = {Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2021},
volume = {1},
number = {1},
pages = {10--26},
doi = {10.51847/wyyopukukf}
}
EUVIMED